177 Lu-Dotatate administration using an infusion pump or a peristaltic pump: comparison of two methods.

التفاصيل البيبلوغرافية
العنوان:	¹⁷⁷ Lu-Dotatate administration using an infusion pump or a peristaltic pump: comparison of two methods.
المؤلفون:	Donzé C; Nuclear medicine department, Institut régional du Cancer de Montpellier (ICM), Univ. Montpellier, Montpellier, France., Rubira L; Nuclear medicine department, Institut régional du Cancer de Montpellier (ICM), Univ. Montpellier, Montpellier, France., Santoro L; Nuclear medicine department, Institut régional du Cancer de Montpellier (ICM), Univ. Montpellier, Montpellier, France., Viarasakd M; Nuclear medicine department, Institut régional du Cancer de Montpellier (ICM), Univ. Montpellier, Montpellier, France., Kotzki PO; Nuclear medicine department, Institut régional du Cancer de Montpellier (ICM), Univ. Montpellier, Montpellier, France.; Institut de Recherche en Cancérologie de Montpellier (IRCM), INSERM U1194, Univ. Montpellier, Institut régional du Cancer de Montpellier (ICM), Montpellier, France., Deshayes E; Nuclear medicine department, Institut régional du Cancer de Montpellier (ICM), Univ. Montpellier, Montpellier, France.; Institut de Recherche en Cancérologie de Montpellier (IRCM), INSERM U1194, Univ. Montpellier, Institut régional du Cancer de Montpellier (ICM), Montpellier, France., Fersing C; Nuclear medicine department, Institut régional du Cancer de Montpellier (ICM), Univ. Montpellier, Montpellier, France cyril.fersing@icm.unicancer.fr.; IBMM, Univ Montpellier, CNRS, ENSCM, Montpellier, France.
المصدر:	European journal of hospital pharmacy : science and practice [Eur J Hosp Pharm] 2024 Apr 23; Vol. 31 (3), pp. 207-211. Date of Electronic Publication: 2024 Apr 23.
نوع المنشور:	Journal Article; Comparative Study
اللغة:	English
بيانات الدورية:	Publisher: BMJ Publishing Group Country of Publication: England NLM ID: 101578294 Publication Model: Electronic Cited Medium: Print ISSN: 2047-9956 (Print) Linking ISSN: 20479956 NLM ISO Abbreviation: Eur J Hosp Pharm Subsets: MEDLINE
أسماء مطبوعة:	Original Publication: London : BMJ Publishing Group
مواضيع طبية MeSH:	Octreotide/analogs & derivatives, Octreotide/administration & dosage , Infusion Pumps/standards , Organometallic Compounds/administration & dosage , Occupational Exposure/prevention & control , Neuroendocrine Tumors*/radiotherapy, Humans ; Radiopharmaceuticals/administration & dosage ; Infusions, Intravenous ; Radiation Exposure/prevention & control
مستخلص:	Objectives: ¹⁷⁷ Lu-oxodotreotide (Lutathera) is an intravenous peptide receptor radionuclide therapy to treat unresectable metastatic digestive neuroendocrine tumours. The recommended method for Lutathera administration is gravity infusion; however, other appropriate and safe techniques are possible. This work compares two infusion methods from a medico-economic, radiation protection, efficiency and practicality point of view. Methods: Two infusion methods were studied, either involving a volumetric infusion pump (method 1) or a peristaltic pump (method 2). For each method, the mean residual activity per vial and the mean injection time were compared. Occupational radiation exposure was measured. The cost of initial equipment and consumables for one administration was determined. Feedback from operators and past incidents during injections were collected through a survey. Results: Three operators performed 219 Lutathera injections over 70 months: 60.7% (133) with method 1 and 39.3% (86) with method 2. After infusion, the mean residual activity in vial was 124.3±16.9 MBq with method 1 and 80.9±19.3 MBq with method 2 (34.9% decrease). The average administration time was 41±7.2 min with method 1 and 39±8.5 min with method 2. Occupational exposures obtained with both methods were very low and quite similar. Method 1 required an initial investment of 1165.8 US$ plus 4.0 US$ of supplies for each administration. Initial investment for method 2 was comparable (1261.4 US$) but supplies cost per administration was higher (12.5 US$). Two major incidents were recorded with method 1 and none with method 2. From operators' experience, method 2 felt safer and more suitable. Conclusions: Method 2 appeared to be convenient and secure, despite a higher cost per injection. It could also be applied to new radioligand therapies such as ¹⁷⁷ Lu-PSMA or ²²⁵ Ac-Dotatate. Competing Interests: Competing interests: None declared. (© European Association of Hospital Pharmacists 2024. No commercial re-use. See rights and permissions. Published by BMJ.)
References:	J Nucl Med. 2002 Feb;43(2):267-72. (PMID: 11850494) J Nucl Med Technol. 2019 Dec;47(4):288-291. (PMID: 31019033) N Engl J Med. 2021 Sep 16;385(12):1091-1103. (PMID: 34161051) J Nucl Med. 2021 Jun 1;62(6):816-822. (PMID: 33246981) J Nucl Med Technol. 2018 Sep;46(3):237-244. (PMID: 30076245) Brachytherapy. 2021 Jan-Feb;20(1):237-247. (PMID: 32819853) AJR Am J Roentgenol. 2018 Aug;211(2):278-285. (PMID: 29949416) Br J Radiol. 2009 Jun;82(978):491-6. (PMID: 19188242) J Nucl Med. 2019 Jul;60(7):937-943. (PMID: 31263080) Nucl Med Commun. 2017 Mar;38(3):266-272. (PMID: 28187040) J Nucl Med. 2018 Dec 20;:. (PMID: 30573642) Cancer Discov. 2018 Apr;8(4):OF2. (PMID: 29487054) Semin Nucl Med. 2020 Sep;50(5):447-464. (PMID: 32768008) J Nucl Med. 2021 Aug 1;62(8):1031-1032. (PMID: 33579808) J Nucl Med Technol. 2014 Jun;42(2):109-13. (PMID: 24799606) N Engl J Med. 2017 Jan 12;376(2):125-135. (PMID: 28076709)
فهرسة مساهمة:	Keywords: antineoplastic agents; drug administration routes; nuclear medicine; quality of health care; safety
المشرفين على المادة:	RWM8CCW8GP (Octreotide) AE221IM3BB (lutetium Lu 177 dotatate) 0 (Organometallic Compounds) 0 (Radiopharmaceuticals)
تواريخ الأحداث:	Date Created: 20220913 Date Completed: 20240424 Latest Revision: 20240426
رمز التحديث:	20240426
مُعرف محوري في PubMed:	PMC11042268
DOI:	10.1136/ejhpharm-2022-003489
PMID:	36100369
قاعدة البيانات:	MEDLINE

Full Text Finder

الوصف
تدمد:	2047-9956
DOI:	10.1136/ejhpharm-2022-003489